Which tumor marker is used to predict response to therapy for cutaneous melanoma and colorectal cancer?

Which tumor marker is used to predict response to therapy for cutaneous melanoma and colorectal cancer?

• A. ALK gene rearrangements
• B. BRAF mutation V600E
• C. CD20
• D. EGFR mutation analysis

Answer: (B)

The BRAF mutation V600E is a significant tumor marker in predicting response to therapy for both cutaneous melanoma and colorectal cancer. Specifically, in cutaneous melanoma, the presence of the BRAF V600E mutation can indicate that the patient may benefit from targeted therapies such as BRAF inhibitors (e.g., vemurafenib, dabrafenib). This mutation is found in a notable percentage of melanomas and has become a critical aspect of personalized treatment approaches. In colorectal cancer, the BRAF V600E mutation is often associated with a poorer prognosis and can help guide therapeutic decisions. Patients with this mutation may not respond well to standard treatments, thus indicating the possibility of using more tailored approaches or clinical trial options. By utilizing BRAF mutation analysis in these cancers, oncologists can better tailor treatment plans to enhance efficacy and improve patient outcomes, making it a pivotal marker in oncology practice for both conditions.

The BRAF mutation V600E is a significant tumor marker in predicting response to therapy for both cutaneous melanoma and colorectal cancer. Specifically, in cutaneous melanoma, the presence of the BRAF V600E mutation can indicate that the patient may benefit from targeted therapies such as BRAF inhibitors (e.g., vemurafenib, dabrafenib). This mutation is found in a notable percentage of melanomas and has become a critical aspect of personalized treatment approaches.

In colorectal cancer, the BRAF V600E mutation is often associated with a poorer prognosis and can help guide therapeutic decisions. Patients with this mutation may not respond well to standard treatments, thus indicating the possibility of using more tailored approaches or clinical trial options.

By utilizing BRAF mutation analysis in these cancers, oncologists can better tailor treatment plans to enhance efficacy and improve patient outcomes, making it a pivotal marker in oncology practice for both conditions.